Howard Lightfoot

Howard Lightfoot

Auto-generated profile, based on publicly available information

Howard Lightfoot

Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2012 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
WYWanjuan Yang
Wanjuan Yang
JSJorge Soares
Jorge Soares
PGPatricia Greninger
Patricia Greninger
EEElena J. Edelman
Elena J. Edelman
HLHoward Lightfoot
Howard Lightfoot
MGMathew J. Garnett
Mathew J. Garnett
Alterations in cancer genomes strongly influence clinical responses to treatment and in many instances are potent biomarkers for response to drugs. The Genomics of Drug Sensitivity in Cancer (GDSC) database (www.cancerRxgene.org) is the largest public resource for information on drug sensitivity in cancer cells and molecular markers of drug response. Data are freely available without restriction. GDSC currently contains drug sensitivity data for almost 75 000 experiments, describing response to 138 anticancer drugs across almost 700 cancer cell lines. To identify molecular markers of drug response, cell line drug sensitivity data are integrated with large genomic datasets obtained from the Catalogue of Somatic Mutations in Cancer database, including information on somatic mutations in cancer genes, gene amplification and deletion, tissue type and transcriptional data. Analysis of GDSC data is through a web portal focused on identifying molecular biomarkers of drug sensitivity based on queries of specific anticancer drugs or cancer genes. Graphical representations of the data are used throughout with links to related resources and all datasets are fully downloadable. GDSC provides a unique resource incorporating large drug sensitivity and genomic datasets to facilitate the discovery of new therapeutic biomarkers for cancer therapies.

1 July 2016 in Cell
Verified
Journal Article
Open access
Francesco IorioFrancesco Iorio
Francesco Iorio
TKTheo A. Knijnenburg
Theo A. Knijnenburg
DVDaniel J. Vis
Daniel J. Vis
GBGraham R. Bignell
Graham R. Bignell
MMMichael P. Menden
Michael P. Menden
MGMathew J. Garnett
Mathew J. Garnett
Systematic studies of cancer genomes have provided unprecedented insights into the molecular nature of cancer. Using this information to guide the development and application of therapies in the clinic is challenging. Here, we report how cancer-driven alterations identified in 11,289 tumors from 29 tissues (integrating somatic mutations, copy number alterations, DNA methylation, and gene expression) can be mapped onto 1,001 molecularly annotated human cancer cell lines and correlated with sensitivity to 265 drugs. We find that cell lines faithfully recapitulate oncogenic alterations identified in tumors, find that many of these associate with drug sensitivity/resistance, and highlight the importance of tissue lineage in mediating drug response. Logic-based modeling uncovers combinations of alterations that sensitize to drugs, while machine learning demonstrates the relative importance of different data types in predicting drug response. Our analysis and datasets are rich resources to link genotypes with cellular phenotypes and to identify therapeutic options for selected cancer sub-populations.

1 September 2016 in Cell
Verified
Journal Article
Open access
ABAlejandra Bruna
Alejandra Bruna
OROscar M. Rueda
Oscar M. Rueda
WGWendy Greenwood
Wendy Greenwood
ABAnkita Sati Batra
Ankita Sati Batra
MCMaurizio Callari
Maurizio Callari
CCCarlos Caldas
Carlos Caldas
The inter- and intra-tumor heterogeneity of breast cancer needs to be adequately captured in pre-clinical models. We have created a large collection of breast cancer patient-derived tumor xenografts (PDTXs), in which the morphological and molecular characteristics of the originating tumor are preserved through passaging in the mouse. An integrated platform combining in vivo maintenance of these PDTXs along with short-term cultures of PDTX-derived tumor cells (PDTCs) was optimized. Remarkably, the intra-tumor genomic clonal architecture present in the originating breast cancers was mostly preserved upon serial passaging in xenografts and in short-term cultured PDTCs. We assessed drug responses in PDTCs on a high-throughput platform and validated several ex vivo responses in vivo. The biobank represents a powerful resource for pre-clinical breast cancer pharmacogenomic studies (http://caldaslab.cruk.cam.ac.uk/bcape), including identification of biomarkers of response or resistance.

16 May 2016 in Pharmacogenomics
Verified
Journal Article
Closed access
DVDaniel J Vis
Daniel J Vis
LBLorenzo Bombardelli
Lorenzo Bombardelli
HLHoward Lightfoot
Howard Lightfoot
Francesco IorioFrancesco Iorio
Francesco Iorio
MGMathew J Garnett
Mathew J Garnett
LWLodewyk Fa Wessels
Lodewyk Fa Wessels
Aim: Experimental variation in dose–response data of drugs tested on cell lines result in inaccuracies in the estimate of a key drug sensitivity characteristic: the IC50. We aim to improve the precision of the half-limiting dose (IC50) estimates by simultaneously employing all dose–responses across all cell lines and drugs, rather than using a single drug–cell line response. Materials & methods: We propose a multilevel mixed effects model that takes advantage of all available dose–response data. Results: The new estimates are highly concordant with the currently used Bayesian model when the data are well behaved. Otherwise, the multilevel model is clearly superior. Conclusion: The multilevel model yields a significant reduction of extreme IC50 estimates, an increase in precision and it runs orders of magnitude faster.

6 April 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
GPGabriele Picco
Gabriele Picco
YRYanhua Rao
Yanhua Rao
ASAngham Al Saedi
Angham Al Saedi
YLYang Lee
Yang Lee
SVSara F. Vieira
Sara F. Vieira
MGMathew J. Garnett
Mathew J. Garnett
Microsatellite-unstable (MSI) cancers require WRN helicase to resolve replication stress due to expanded DNA (TA)n dinucleotide repeats. WRN is a promising synthetic lethal target for MSI tumors, and WRN inhibitors are in development. In this study, we used CRISPR–Cas9 base editing to map WRN residues critical for MSI cells, validating the helicase domain as the primary drug target. Fragment-based screening led to the development of potent and highly selective WRN helicase covalent inhibitors. These compounds selectively suppressed MSI model growth in vitro and in vivo by mimicking WRN loss, inducing DNA double-strand breaks at expanded TA repeats and DNA damage. Assessment of biomarkers in preclinical models linked TA-repeat expansions and mismatch repair alterations to compound activity. Efficacy was confirmed in immunotherapy-resistant organoids and patient-derived xenograft models. The discovery of potent, selective covalent WRN inhibitors provides proof of concept for synthetic lethal targeting of WRN in MSI cancer and tools to dissect WRN biology. Significance: We report the discovery and characterization of potent, selective WRN helicase inhibitors for MSI cancer treatment, with biomarker analysis and evaluation of efficacy in vivo and in immunotherapy-refractory preclinical models. These findings pave the way to translate WRN inhibition into MSI cancer therapies and provide tools to investigate WRN biology. See related commentary by Wainberg, p. 1369

8 March 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
ABAzadeh C. Bashi
Azadeh C. Bashi
ECElizabeth A. Coker
Elizabeth A. Coker
KBKrishna C. Bulusu
Krishna C. Bulusu
PJPatricia Jaaks
Patricia Jaaks
CCClaire Crafter
Claire Crafter
MGMathew J. Garnett
Mathew J. Garnett
Oncology drug combinations can improve therapeutic responses and increase treatment options for patients. The number of possible combinations is vast and responses can be context-specific. Systematic screens can identify clinically relevant, actionable combinations in defined patient subtypes. We present data for 109 anticancer drug combinations from AstraZeneca's oncology small molecule portfolio screened in 755 pan-cancer cell lines. Combinations were screened in a 7 × 7 concentration matrix, with more than 4 million measurements of sensitivity, producing an exceptionally data-rich resource. We implement a new approach using combination Emax (viability effect) and highest single agent (HSA) to assess combination benefit. We designed a clinical translatability workflow to identify combinations with clearly defined patient populations, rationale for tolerability based on tumor type and combination-specific “emergent” biomarkers, and exposures relevant to clinical doses. We describe three actionable combinations in defined cancer types, confirmed in vitro and in vivo, with a focus on hematologic cancers and apoptotic targets. Significance: We present the largest cancer drug combination screen published to date with 7 × 7 concentration response matrices for 109 combinations in more than 750 cell lines, complemented by multi-omics predictors of response and identification of “emergent” combination biomarkers. We prioritize hits to optimize clinical translatability, and experimentally validate novel combination hypotheses. This article is featured in Selected Articles from This Issue, p. 695